Hepatitis

  • Most Topular Stories

  • Advocates Criticize Plans to Restrict N.Y. Hepatitis C Drugs

    Hepatitis News
    21 Oct 2014 | 6:02 pm
    The National AIDS Treatment Advocacy Project and others have sent a letter to Governor Andrew Cuomo and Howard A. Zucker, MD, of the New York State Department of Health, urging them to reconsider plans to restrict access to new hepatitis C virus treatments, according to a NATAP press release . The letter comes in response to a September 18 legislative meeting in which state officials recommended the state Medicaid board include several restrictions on access to Sovaldi from Gilead Sciences.
  • ABT-450/r plus ombitasvir and dasabuvir - Oral Combo Tx Soars in HCV

    HCV New Drug Research
    20 Oct 2014 | 5:35 pm
    Meeting CoverageOral Combo Tx Soars in HCVIn one large international study, 99.3% of patients infected with genotype 1b receiving ABT-450/r plus ombitasvir and dasabuvir -- the direct-acting 3D regimen -- without ribavirin showed sustained virologic responses at 12 weeks (SVR12), as did 98.7% of those who were given that regimen plus ribavirin, Andreas Maieron, MD, of Elisabeth Hospital in Linz, Austria, reported during the presidential plenary session at the annual meeting of the American College of Gastroenterology.Published: Oct 20, 2014By Nancy Walsh, Senior Staff Writer, MedPage…
  • What's the Difference Between Acute and Chronic...

    About.com Hepatitis: What's Hot Now
    hepatitis.guide@about.com
    22 Oct 2014 | 4:14 am
    Hepatitis B is a disease caused by the hepatitis B virus, and can be acute or chronic. Infection with hepatitis B virus is the leading cause of chronic hepatitis worldwide and people with chronic hepatitis B infection are at increased risk for developing liver cancer. In addition, the hepatitis B virus is the leading cause of cirrhosis in the world. Page 2.
  • Dropout Rate for Taking Sovaldi: 400% Higher Than Observed in Clinical Trials

    Hepatitis Central
    The Editors at Hepatitis Central
    7 Oct 2014 | 6:47 am
    CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill By David Kroll, 9/17/14 Over 8 percent of hepatitis C patients taking Sovaldi (sofosbuvir; Gilead) are failing to complete their full, 12-week course of drug therapy, a dropout rate roughly four times that observed in clinical trials. By discontinuing the drug, shown to have a 90+% cure rate, these patients (and their insurance providers) are incurring health care costs of $28,000 or $56,000, without knowing if they are rid of the virus. Continue reading this entire article:…
  • SummonChimera infers integrated viral genomes with nucleotide precision from NGS data

    MedWorm: Hepatitis B
    21 Oct 2014 | 4:00 pm
    Conclusions: SummonChimera identified all experimentally verified chimeras detected by current computational methods. Further, SummonChimera integration inference precisely predicted bacteriophage integration. The application of SummonChimera to cancer NGS accurately identifies deletion of host and viral sequence during integration. The precise nucleotide determination of an integration allows prediction of viral and cellular gene transcription patterns. (Source: Epidemiologic Perspectives and Innovations)MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space...
  • add this feed to my.Alltop

    MedWorm: Hepatitis B

  • SummonChimera infers integrated viral genomes with nucleotide precision from NGS data

    21 Oct 2014 | 4:00 pm
    Conclusions: SummonChimera identified all experimentally verified chimeras detected by current computational methods. Further, SummonChimera integration inference precisely predicted bacteriophage integration. The application of SummonChimera to cancer NGS accurately identifies deletion of host and viral sequence during integration. The precise nucleotide determination of an integration allows prediction of viral and cellular gene transcription patterns. (Source: Epidemiologic Perspectives and Innovations)MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space...
  • [Articles] HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study

    20 Oct 2014 | 10:15 pm
    Screening for viral hepatitis is important in individuals diagnosed as HIV positive. Effective management for viral hepatitis should be integrated into HIV treatment programmes. Long-term data are needed about the effect of hepatitis co-infection on HIV disease progression. (Source: The Lancet Infectious Diseases)
  • [Comment] Hepatitis virus and HIV interactions

    20 Oct 2014 | 10:15 pm
    Because of shared routes of transmission, 5–25% of the 34 million people with HIV worldwide are co-infected with either hepatitis B virus (HBV), hepatitis C virus (HCV), or both, with the highest number of co-infections in low-income countries. The negative effect of HIV infection on the progression of HBV and HCV infection is well established, with high rates of viral persistence, higher hepatitis viral load, and a more rapid progression to liver fibrosis and hepatocellular carcinoma in HIV-positive patients. (Source: The Lancet Infectious Diseases)
  • The Immunobiology of Hepatitis B Virus Infection

    19 Oct 2014 | 4:00 pm
    Abstract The adaptive immune response, particularly the virus‐specific CD8+ T cell response, is largely responsible for viral clearance and disease pathogenesis during hepatitis B virus (HBV) infection. The HBV‐specific CD8+ T cell response is vigorous, polyclonal and multispecific in acutely infected patients who successfully clear the virus and relatively weak and narrowly focused in chronically infected patients. The immunological basis for this dichotomy is unclear. A recent study using HBV transgenic mice and HBV‐specific T cell receptor (TCR) transgenic mice suggests that…
  • Vaccines and MS

    19 Oct 2014 | 3:00 pm
    A study found no association between hepatitis B and human papillomavirus (HPV) vaccines and an increased risk of MS up to three years after vaccination. Medical News Today Science 2.0 Vaccination and immunisation - A to Z of MS (Source: Multiple Sclerosis Trust)
 
  • add this feed to my.Alltop

    About.com Hepatitis: What's Hot Now

  • What's the Difference Between Acute and Chronic...

    hepatitis.guide@about.com
    22 Oct 2014 | 4:14 am
    Hepatitis B is a disease caused by the hepatitis B virus, and can be acute or chronic. Infection with hepatitis B virus is the leading cause of chronic hepatitis worldwide and people with chronic hepatitis B infection are at increased risk for developing liver cancer. In addition, the hepatitis B virus is the leading cause of cirrhosis in the world. Page 2.
  • Can You Get Hepatitis C from Getting a Tattoo?

    hepatitis.guide@about.com
    22 Oct 2014 | 4:14 am
    Is there a link between hepatitis and tattoos? Yes, there is and here's how you can protect yourself.
  • Will You Need a Liver Transplant?

    hepatitis.guide@about.com
    22 Oct 2014 | 4:14 am
    Liver transplantation is the best treatment for some patients with acute or chronic liver disease that is progressive and life-threatening.
  • Chronic Hepatitis B Drugs

    hepatitis.guide@about.com
    22 Oct 2014 | 4:14 am
    Chronic hepatitis B has several approved drugs for treatment. Here are hepatitis B drugs and some of their pros and cons.
  • Antibody

    hepatitis.guide@about.com
    22 Oct 2014 | 4:14 am
    Definition of antibody. Hepatitis.
 
  • add this feed to my.Alltop

    Hepatitis Central

  • Dropout Rate for Taking Sovaldi: 400% Higher Than Observed in Clinical Trials

    The Editors at Hepatitis Central
    7 Oct 2014 | 6:47 am
    CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill By David Kroll, 9/17/14 Over 8 percent of hepatitis C patients taking Sovaldi (sofosbuvir; Gilead) are failing to complete their full, 12-week course of drug therapy, a dropout rate roughly four times that observed in clinical trials. By discontinuing the drug, shown to have a 90+% cure rate, these patients (and their insurance providers) are incurring health care costs of $28,000 or $56,000, without knowing if they are rid of the virus. Continue reading this entire article:…
  • The Affordability of Sovaldi

    Nicole Cutler L.Ac.
    1 Oct 2014 | 12:29 pm
    Sovaldi is currently one of the best medications approved to defeat the tenacious Hepatitis C virus. With a price tag of $1,000 per pill, this drug’s cost is probably its biggest caveat. The World Health Organization estimates that 130 million people have been infected with Hepatitis C, and many of those are far from able to afford the $84,000 needed for Sovaldi’s twelve weeks of treatment. However, the price of $1,000 per pill does not seem to apply to everyone. Besides differences in what U.S. health insurers will cover, generic licensing of Sovaldi in developing countries will…
  • Similar, But Different – Hepatitis C Co-Infection and Superinfection

    Nicole Cutler L.Ac.
    16 Sep 2014 | 7:40 am
    Infecting an estimated 150 million people worldwide, the Hepatitis C virus has proven itself to be a tenacious foe. A leading cause of chronic liver disease, cirrhosis and liver cancer, there is not yet a vaccine to prevent Hepatitis C, and experts believe many are unknowingly infected. Once diagnosis has been made, treatment is arduous and may be ineffective for 10 to 50 percent who begin a cocktail of potent medications. Battling one strain of hepatitis is hard enough, but some people have more than one infection. As a blood borne virus, Hepatitis C is spread via blood-to-blood contact.
  • Say it Ain’t So…New Hep C Drug to Surpass $84,000

    The Editors at Hepatitis Central
    15 Sep 2014 | 9:27 am
    Gilead to raise price for new hepatitis C drug above $84,000 By Deena Beasley September 12, 2014 (Reuters) – The next generation version of Gilead Sciences Inc’s $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive. Gregg Alton, Gilead’s executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month. Continue reading this entire article:…
  • How Quickly Can HCV be Eradicated?

    The Editors at Hepatitis Central
    11 Sep 2014 | 9:48 am
    Telaprevir Treatment Decays Hepatitis C Virus Faster in Blood than Liver By Catherine Kolonko | September 10, 2014 A recent study found that the hepatitis C virus decays during treatment with telaprevir faster in the bloodstream than it does in the liver, a discovery that could help pinpoint how long a patient needs to take medicine to rid the virus from the body. The study was conducted by Andrew Talal, MD, and other researchers at Weill Cornell Medical College in New York City and the findings published in Hepatology. It was the first time scientists traced in real time how the drug…
 
  • add this feed to my.Alltop

    Hepatitis News

  • [Herald Interview] Graphene oxide new tool in fight against diseases

    22 Oct 2014 | 8:44 am
    A leading South Korean biochemistry researcher believes graphene oxide - oxidized sheets of carbon atoms - will eventually play a key role in conquering hepatitis C, cancer and genetic diseases. This is mainly because graphene oxide is water-soluble, and can bind to DNA and RNA molecules - making it more convenient for medical uses.
  • New pill-only regimens cure patients with hardest-to-treat hepatitis C infection

    22 Oct 2014 | 5:02 am
    Two new pill-only regimens that rapidly cure most patients with genotype 1 hepatitis C infection could soon be widely prescribed across Europe. Two recently-published studies1,2 confirmed the efficacy and safety of combination therapy with two oral direct-acting antiviral agents , with around 90% of patients cured after just 12-weeks of treatment.
  • My view: New treatment can cure Hepatitis C

    22 Oct 2014 | 1:21 am
    Hepatitis C, a potentially deadly inflammation of the liver, afflicts more than 3.2 million Americans. Around 70 percent of them will develop chronic liver disease, and as many as 5 percent will die from cirrhosis or liver cancer.
  • New Drugs to Treat Hepatitis C

    21 Oct 2014 | 9:41 pm
    For many years, treating the virus Hepatitis C has meant injections, long courses of treatment with awful side effects, and a very low cure rate. Doctors at Geisinger met to talk with us about new drugs that they're calling "game changers" in their fight against Hep C. If you are a baby boomer, the Centers for Disease Control and Prevention wants you to get tested for Hepatitis C. The virus can do extensive damage to the liver.
  • Advocates Criticize Plans to Restrict N.Y. Hepatitis C Drugs

    21 Oct 2014 | 6:02 pm
    The National AIDS Treatment Advocacy Project and others have sent a letter to Governor Andrew Cuomo and Howard A. Zucker, MD, of the New York State Department of Health, urging them to reconsider plans to restrict access to new hepatitis C virus treatments, according to a NATAP press release . The letter comes in response to a September 18 legislative meeting in which state officials recommended the state Medicaid board include several restrictions on access to Sovaldi from Gilead Sciences.
 
  • add this feed to my.Alltop

    Hepatitis Blog

  • Hepatitis A Cluster in Alabama

    Bill Marler
    27 Sep 2014 | 9:29 am
    The Alabama Department of Public Health is investigating three cases of hepatitis A in Clarke County in southwest Alabama. The department says two of the cases involve people who have a history of international travel. The health department says signs of hepatitis A appear 15 to 50 days after exposure and commonly include mild fever, loss of appetite, nausea, vomiting and tiredness. The disease varies in severity from about two weeks to six weeks or more. The department says casual contact, such as at an office or school, does not transmit the virus. The risk increases when people are in…
  • 165 Sick with Hepatitis A Linked to Townsend Farms Organic Antioxidant Blend

    Bill Marler
    25 Sep 2014 | 9:52 pm
    165 people were confirmed to have become ill from hepatitis A after eating ‘Townsend Farms Organic Antioxidant Blend’ in 10 states: Arizona (24), California (80), Colorado (29), Hawaii (8), New Hampshire (1), New Jersey (1), New Mexico (11), Nevada (6), Utah (3), and Wisconsin (2). [Note: The cases reported from Wisconsin resulted from exposure to the product in California, the cases reported from New Hampshire reported fruit exposure during travel to Nevada, and the case reported in New Jersey was a household contact of a confirmed case from Colorado.] Eight of the confirmed cases were…
  • Whataburger Linked to Hepatitis A Scare

    Bill Marler
    21 Aug 2014 | 9:12 pm
    Austin Texas health officials are alerting the public about possible hepatitis A exposure at a Whataburger in Central Austin. A restaurant employee there at the 2800 Guadalupe St. location has been diagnosed with the hepatitis A virus. Hepatitis A is a contagious liver disease that is usually spread when a person ingests something that has been contaminated with the feces of an infected person, including contaminated food or water. Signs and symptoms of hepatitis A can include the following Fever Fatigue Loss of appetite Nausea Vomiting Abdominal discomfort Dark urine Clay-colored bowel…
  • Another Reason for Hepatitis A Vaccines – Your Restaurant Remains Closed

    Bill Marler
    19 Jul 2014 | 5:09 am
    Tortilla Marissa’s, a Mexican restaurant in Fort Collins, CO, will not reopen until August 9 because of the Hepatitis A scare that the restaurant faced at the end of June, according to the Coloradoan. The Larimer County Health Department has advised the owners to keep the restaurant closed that long due to the virus’ relatively long incubation period, which averages 28 days but can last up to 50 days in some cases. The restaurant originally closed on June 27, a day after an employee tested positive for the virus, which has a high risk of being spread when an infected person handles…
  • Another Hepatitis A Scare: Tortilla Marissa’s Restaurant Worker

    Bill Marler
    28 Jun 2014 | 7:46 am
    The Larimer County Department of Health and Environment is advising the public about a possible exposure to hepatitis A virus at the Tortilla Marissa’s restaurant located at 2635 S. College Avenue in Fort Collins. A food worker employed at Tortilla Marissa has tested positive for hepatitis A, a disease that might be passed to others through food directly handled by the employee before any symptoms appeared.  The restaurant is cooperating fully in the investigation and has agreed to voluntarily close until approved by the Department to reopen.  The risk of transmission to others occurred…
  • add this feed to my.Alltop

    HCV New Drug Research

  • Reform Update: Medicaid programs crafting limits on Harvoni usage

    22 Oct 2014 | 5:33 am
    Reform Update: Medicaid programs crafting limits on Harvoni usageBy Virgil Dickson Posted: October 21, 2014 - 4:15 pm ET Tags: Access, Government, Healthcare Reform, Medicaid, Pharmaceuticals, SuppliersWhich Medicaid beneficiaries will have access to Gilead Sciences' newest high-cost hepatitis C treatment, Harvoni, and when they'll get that access, now depends on prior-authorization criteria being hammered out by various state agencies.Most will likely limit Harvoni use to patients dealing with liver failure, as 35 states now do for Gilead's Sovaldi. Some may adopt restrictions such as…
  • Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst

    22 Oct 2014 | 5:12 am
    Source -  European  Pharmaceutical ReviewHarvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData AnalystThe recent US Food and Drug Administration (FDA) approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to maintain its dominance in an increasingly competitive market, says an analyst with research and consulting firm GlobalData.Christopher J. Pace, Ph.D., GlobalData’s Senior Analyst covering Infectious…
  • ACG 2014 - New and upcoming therapies for the treatment of HCV

    21 Oct 2014 | 12:08 pm
    See more from Highlights from ACG 2014PHILADELPHIA — In this exclusive video interview, Paul Y. Kwo, MD, professor of medicine, Indiana University, discusses the new and upcoming therapies, including the recently approved combination regimen of ledipasvir and sofosbuvir, to treat patients with hepatitis C virus infection. He further discusses how the new therapies will impact patients within this specific population in the future.“With a lot of hard work, we should be able to successfully treat and eradicate this disease within the next several decades,” Kwo said.Disclosure: Kwo holds…
  • Enanta update on collaboration agreement with AbbVie

    21 Oct 2014 | 5:16 am
    Enanta Pharmaceuticals provides update on its collaboration agreement with AbbVieEnanta Pharmaceuticals, a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, has announced that it has decided not to exercise its co-development option for ABT-493, Enanta’s next-generation protease inhibitor for hepatitis C virus (HCV) being developed in Enanta’s collaboration with AbbVie.Per the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well…
  • ABT-450/r plus ombitasvir and dasabuvir - Oral Combo Tx Soars in HCV

    20 Oct 2014 | 5:35 pm
    Meeting CoverageOral Combo Tx Soars in HCVIn one large international study, 99.3% of patients infected with genotype 1b receiving ABT-450/r plus ombitasvir and dasabuvir -- the direct-acting 3D regimen -- without ribavirin showed sustained virologic responses at 12 weeks (SVR12), as did 98.7% of those who were given that regimen plus ribavirin, Andreas Maieron, MD, of Elisabeth Hospital in Linz, Austria, reported during the presidential plenary session at the annual meeting of the American College of Gastroenterology.Published: Oct 20, 2014By Nancy Walsh, Senior Staff Writer, MedPage…
 
Log in